MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12325-016-0391-9

Медицинская библиотека · Advances in therapy · 2016

The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.

Castaneda Saul, Melendez-Lopez Samuel, Garcia Esbeydy, De la Cruz Hermelinda, Sanchez-Palacio Jose

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5-10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, because in many countries there are no treatment protocols or propranolol formulations appropriate for the pediatric population. The objective of the present study was to evaluate the impact of pharmacist interventions such as detecting, analyzing, and solving problems presented during treatment with propranolol in patients with IH.

METHODS

An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol. Pharmacist participation consisted of development of an extemporaneous formulation and counseling the child's parents. At each visit to the pharmacy service, family members were interviewed, detecting and classifying problems related to treatment.

RESULTS

Sixty-three children with IH were treated during the period under review. Patient ages ranged from 3 to 11 months old; 64% were female and 36% were male. Forty-nine problems in 30 patients were detected, principally inadequate dose (18.4%), non-adherence to treatment (16.3%), side effects (14.3%), and wrong administration (14.3%). Of the problems detected, 81.6% were resolved. Interventions by the pharmacist in 27 patients were intensive counseling on adherence to therapy (20%), detection of adverse effects (11.4%), and adjustment of the dose (22.9%). In 95.2% of patients a good response to treatment was obtained compared with 77.2% reported in European studies without pharmacist intervention.

CONCLUSION

It seems that pharmacist participation increases adherence to treatment and reduces the likelihood of adverse effects, allowing for safe and effective therapy in patients with IH.

Для цитирования: Castaneda Saul, Melendez-Lopez Samuel, Garcia Esbeydy, De la Cruz Hermelinda, Sanchez-Palacio Jose. The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.. Advances in therapy. 2016. DOI: 10.1007/s12325-016-0391-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.